This National Institute on Aging (NIA) grant is for developing multi-target disease-modifying therapeutics for Alzheimer’s Disease-Related Dementias (AD/ADRD). Its purpose is to validate synergistic interactions among multiple biological targets, addressing the disease’s complex pathways. Research supports single drugs or biologics targeting multiple pathways, or combination therapies. The R61 phase funds hypothesis testing on beneficial interactions and mechanisms. The R33 phase ensures rigorous validation of multi-target approaches. This initiative aims to accelerate comprehensive AD/ADRD treatment strategies, positioning awardees for future translational funding.
Opportunity ID: 348829
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-23-195 |
| Funding Opportunity Title: | Simultaneous and Synergistic Multi-Target Validation for Alzheimers Disease-Related Dementias (R61/R33 Clinical Trial not allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 21, 2023 |
| Last Updated Date: | Jun 21, 2023 |
| Original Closing Date for Applications: | Sep 15, 2023 |
| Current Closing Date for Applications: | Sep 15, 2023 |
| Archive Date: | Oct 21, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $499,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments County governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses State governments Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Private institutions of higher education City or township governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The ultimate goal is to develop multi-target disease-modifying therapeutics based on an appreciation of the complex interaction of pathways, cells, circuits, systems or pathologies that are present in complex AD/ADRD diagnoses. Such therapeutics could be a single drug or biologic targeting multiple pathways, cell, circuits, systems or pathologies, or could be a combination of therapies. While hundreds of possible targets have been suggested for AD alone, theres a need to better understand how multiple targets might interact in a synergistic way that would allow us to tackle AD/ADRD from multiple fronts in a single person, akin to what has been successful in infectious disease or cancer. This FOA will support applications that test hypotheses of possible beneficial interactions of known targets as well as understanding the mechanisms of interaction in the R61. The R33 would support rigorous validation of the proposed multi-target approach (one drug or biologic targeting multiple pathways; and/or a combination of therapies) to support future multi-target therapy development efforts. Successful grantees will be in position to apply for IGNITE or other similar translational grant mechanisms. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-23-195.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 348829 Full Announcement-PAR-23-195 -> PAR-23-195-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00282245 | Aug 15, 2023 | Sep 15, 2023 | View |
Package 1
Mandatory forms
348829 RR_SF424_5_0-5.0.pdf
348829 PHS398_CoverPageSupplement_5_0-5.0.pdf
348829 RR_OtherProjectInfo_1_4-1.4.pdf
348829 PerformanceSite_4_0-4.0.pdf
348829 RR_KeyPersonExpanded_4_0-4.0.pdf
348829 RR_Budget10_3_0-3.0.pdf
348829 PHS398_ResearchPlan_5_0-5.0.pdf
348829 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
348829 RR_SubawardBudget10_30_3_0-3.0.pdf
348829 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
